175 related articles for article (PubMed ID: 32681675)
21. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
[TBL] [Abstract][Full Text] [Related]
22. Neurology of the acute hepatic porphyrias.
Oliveira Santos M; Leal Rato M
J Neurol Sci; 2021 Sep; 428():117605. PubMed ID: 34375916
[TBL] [Abstract][Full Text] [Related]
23. The epidemiology of hepatocellular carcinoma in patients with acute intermittent porphyria.
Andersson C; Bjersing L; Lithner F
J Intern Med; 1996 Oct; 240(4):195-201. PubMed ID: 8918510
[TBL] [Abstract][Full Text] [Related]
24. Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan.
Akuta N; Kawamura Y; Suzuki F; Saitoh S; Arase Y; Kunimoto H; Sorin Y; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Kobayashi M; Ikeda K; Kumada H
Hepatol Int; 2016 Jul; 10(4):647-56. PubMed ID: 27074850
[TBL] [Abstract][Full Text] [Related]
25. Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey.
Chalasani N; Said A; Ness R; Hoen H; Lumeng L
Am J Gastroenterol; 1999 Aug; 94(8):2224-9. PubMed ID: 10445554
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of Undiagnosed Acute Hepatic Porphyria in Cyclic Vomiting Syndrome and Overlap in Clinical Symptoms.
Cheng S; Yu E; Garacci Z; Erwin AL; Venkatesan T
Dig Dis Sci; 2023 May; 68(5):2107-2114. PubMed ID: 36380150
[TBL] [Abstract][Full Text] [Related]
27. Sick leave, disability, and mortality in acute hepatic porphyria: a nationwide cohort study.
Baravelli CM; Aarsand AK; Sandberg S; Tollånes MC
Orphanet J Rare Dis; 2020 Feb; 15(1):56. PubMed ID: 32085780
[TBL] [Abstract][Full Text] [Related]
28. Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period.
Pais R; Fartoux L; Goumard C; Scatton O; Wendum D; Rosmorduc O; Ratziu V
Aliment Pharmacol Ther; 2017 Nov; 46(9):856-863. PubMed ID: 28857208
[TBL] [Abstract][Full Text] [Related]
29. Clinical characteristics analysis of 1180 patients with hepatocellular carcinoma secondary to hepatitis B, hepatitis C and alcoholic liver disease.
Zhao H; Zhu P; Han T; Ye Q; Xu C; Wu L; Liu F; Yin W; Li Z; Guo Y
J Clin Lab Anal; 2020 Feb; 34(2):e23075. PubMed ID: 31659795
[TBL] [Abstract][Full Text] [Related]
30. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis.
Pekow JR; Bhan AK; Zheng H; Chung RT
Cancer; 2007 Jun; 109(12):2490-6. PubMed ID: 17487861
[TBL] [Abstract][Full Text] [Related]
31. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.
Ioannou GN; Green P; Kerr KF; Berry K
J Hepatol; 2019 Sep; 71(3):523-533. PubMed ID: 31145929
[TBL] [Abstract][Full Text] [Related]
32. Hepatocellular carcinoma in Germany: a retrospective epidemiological study from a low-endemic area.
Kubicka S; Rudolph KL; Hanke M; Tietze MK; Tillmann HL; Trautwein C; Manns M
Liver; 2000 Jul; 20(4):312-8. PubMed ID: 10959810
[TBL] [Abstract][Full Text] [Related]
33. Hepatocellular carcinoma in porphyria cutanea tarda: frequency and factors related to its occurrence.
Siersema PD; ten Kate FJ; Mulder PG; Wilson JH
Liver; 1992 Apr; 12(2):56-61. PubMed ID: 1320175
[TBL] [Abstract][Full Text] [Related]
34. The clinical importance of early acute hepatic porphyria diagnosis: a national cohort.
Edel Y; Mamet R; Cohen S; Shepshelovich D; Levi A; Sagy I
Intern Emerg Med; 2021 Jan; 16(1):133-139. PubMed ID: 32372331
[TBL] [Abstract][Full Text] [Related]
35. Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria.
Kardashian A; Florman SS; Haydel B; Ruiz RM; Klintmalm GB; Lee DD; Taner CB; Aucejo F; Tevar AD; Humar A; Verna EC; Halazun KJ; Chapman WC; Vachharajani N; Hoteit M; Levine MH; Nguyen MH; Melcher ML; Langnas AN; Carney CA; Mobley C; Ghobrial M; Amundsen B; Markmann JF; Sudan DL; Jones CM; Berumen J; Hemming AW; Hong JC; Kim J; Zimmerman MA; Nydam TL; Rana A; Kueht ML; Fishbein TM; Markovic D; Busuttil RW; Agopian VG
Hepatology; 2020 Dec; 72(6):2014-2028. PubMed ID: 32124453
[TBL] [Abstract][Full Text] [Related]
36. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.
Ascha MS; Hanouneh IA; Lopez R; Tamimi TA; Feldstein AF; Zein NN
Hepatology; 2010 Jun; 51(6):1972-8. PubMed ID: 20209604
[TBL] [Abstract][Full Text] [Related]
37. Predictive factors for risk of hepatocellular carcinoma in immune inactive chronic hepatitis B.
Seo SI; Kim HS; Yang BK; Kang JG; Shin WG; Lee JH; Kim HY; Jang MK
Clin Res Hepatol Gastroenterol; 2020 Oct; 44(5):711-717. PubMed ID: 31959567
[TBL] [Abstract][Full Text] [Related]
38. Incidence and risk factors of hepatocellular carcinoma in patients with hepatic venous outflow tract obstruction.
Paul SB; Shalimar ; Sreenivas V; Gamanagatti SR; Sharma H; Dhamija E; Acharya SK
Aliment Pharmacol Ther; 2015 May; 41(10):961-71. PubMed ID: 25809735
[TBL] [Abstract][Full Text] [Related]
39. The accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis B.
Chon YE; Jung ES; Park JY; Kim DY; Ahn SH; Han KH; Chon CY; Jung KS; Kim SU
J Clin Gastroenterol; 2012 Jul; 46(6):518-25. PubMed ID: 22688146
[TBL] [Abstract][Full Text] [Related]
40. Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis.
Kim MN; Kim BK; Kim SU; Park JY; Ahn SH; Han KH; Kim DY
Scand J Gastroenterol; 2019 Oct; 54(10):1283-1290. PubMed ID: 31593481
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
